Compare Incyte Corporation (INCY) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Oxford Lane Capital Corp — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Oxford Lane Capital Corp trades at $8.56 (market cap $835.71M). The key difference: Incyte Corporation is far larger — about 27.3× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 28.15% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Oxford Lane Capital Corp for 50 Days on average.
| INCY | OXLC | |
|---|---|---|
Market Cap | $22.85B | $835.71M |
Volume | 1,927,029 | 1,125,263 |
Sector | Health | Financials |
52-Week High | $129.93 | $16.66 |
52-Week Low | $83.80 | $8.15 |
Typical Hold Time | 33 Days | 50 Days |
Enterprise Value | $18.35B | $1.23B |
Dividend Yield | — | 28.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
OXLC trades at $8.53, up 0.83% on the day, with a bearish technical outlook from moving averages. The stock shows mixed signals: a low P/B of 0.81 suggests undervaluation, but profitability metrics are deeply negative with an ROE of -39.16% and recent quarterly earnings misses. The company maintains a $0.20 monthly dividend, yet cash flow from operations was negative $703.80M in 2025, offset by financing inflows.
Outlook is highly speculative. The deep discount to book value and high dividend yield may attract income seekers, but substantial earnings volatility, negative cash generation, and a 50% analyst buy rating reflect significant operational and financial risks. Investor caution is warranted given the bearish technicals and fundamental pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
